Case Report Shows Carbimazole's ‘Triple-Hit’ - Summary - MDSpire

Case Report Shows Carbimazole's ‘Triple-Hit’

Diffuse alveolar hemorrhage with coexistent antiphospholipid syndrome complicated anticoagulation therapy and created competing bleeding and thrombosis risks.

  • By

  • Andrea Surnit

  • April 1, 2026

  • 3 min

Share

Objective:

To report a case of a patient with long-term carbimazole use who developed microscopic polyangiitis with diffuse alveolar hemorrhage and antiphospholipid syndrome, highlighting the complexities of treatment.

Key Findings:
  • The patient developed a 'triple-hit' condition involving vasculitis, thrombosis, and immune-complex deposition, complicating treatment.
  • Disease activity was significant with a BVAS score of 14 and APS classification score of 10, influencing management strategies.
  • Rapid plasmapheresis was crucial for stabilizing the pulmonary system, allowing for safe future interventions.
Interpretation:

The case illustrates the complexities of managing concurrent vasculitis and antiphospholipid syndrome, highlighting the need for careful treatment planning and interdisciplinary collaboration.

Limitations:
  • The findings are based on a single patient, limiting generalizability and potential biases.
  • Additional immunologic characterization was not performed due to resource constraints.
Conclusion:

The case emphasizes the importance of rapid intervention in severe cases and the potential for safe reintroduction of carbimazole post-stabilization, with ongoing monitoring.

Original Source(s)

Case Report Shows Carbimazole's ‘Triple-Hit’

  • by Andrea Surnit

  • April 1, 2026

Related Content

Obesity Not Associated With Worse Long-Term TAR Outcomes

A long-term cohort study found that obesity was not associated with worse patient-reported outcomes or higher reoperation rates following total ankle replacement in optimized surgical candidates.

Antibiotic Falls Short in Disc-Related Back Pain

A randomized trial found no greater pain reduction vs placebo, but questions remain about patients with type 1 Modic changes.

Serum Urate Goals Tied to Lower CV Risk

Patients with gout who reached serum urate targets had modestly higher 5-year cardiovascular event-free survival, with associations strongest among high-risk patients